9 news items
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
RYTM
22 May 24
. Corporate Contact:David ConnollyHead of Investor Relations and Corporate CommunicationsRhythm Pharmaceuticals
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
RYTM
6 May 24
Head of Investor Relations and Corporate Communications Rhythm Pharmaceuticals, Inc. 857-264-4280
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
RYTM
29 Apr 24
. Corporate Contact:David ConnollyHead of Investor Relations and Corporate CommunicationsRhythm
Analyst Expectations For Rhythm Pharmaceuticals's Future
RYTM
26 Apr 24
, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
RYTM
24 Apr 24
Relations and Corporate CommunicationsRhythm Pharmaceuticals, Inc.857-264-4280
9wxpp3kn4swe88uk8b3stsxu30vtl4e3wedkn
RYTM
16 Apr 24
:David ConnollyHead of Investor Relations and Corporate CommunicationsRhythm Pharmaceuticals, Inc.857-264
3rttyd56gczft 1tsfdc2oyvpw
RYTM
10 Apr 24
calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts
be8b4s vd791l6r
RYTM
11 Mar 24
Contact:David ConnollyHead of Investor Relations and Corporate CommunicationsRhythm Pharmaceuticals, Inc
d0zyqo9eot86w
RYTM
6 Mar 24
. Corporate Contact:David ConnollyHead of Investor Relations and Corporate CommunicationsRhythm Pharmaceuticals
- Prev
- 1
- Next